Medicus Pharma Ltd.
BioSniper AI · MDCX
Medicus Pharma Ltd. (MDCX) is a biotech/life sciences company advancing two clinical-stage programs: SkinJect (non-invasive treatment for non-melanoma skin cancer) and Teverelix (a GnRH antagonist for oncology and women's health), with recent Phase 2 data and regulatory submissions supporting registrational development.
Key risk: Clinical trial failure risk
Spotter reads the filings and answers with citations.
BioSniper Score
Based on 4 of 6 signals
Tracking 2 pipeline candidates for Medicus Pharma Ltd. · Updated within the last hour.
Medicus Pharma Ltd. (MDCX) is a biotech/life sciences company advancing two clinical-stage programs: SkinJect (non-invasive treatment for non-melanoma skin cancer) and Teverelix (a GnRH antagonist for oncology and women's health), with recent Phase 2 data and regulatory submissions supporting registrational development.
- Announced a $22 million non-dilutive financing on May 28, 2026, extending projected operating cash runway for over two years [news · 2026-05-28].
- Reported 55% complete response at Day 57 for the 200µg cohort in the expanded Phase 2 SKNJCT-003 study of SkinJect for basal cell carcinoma, emerging as a registrational-grade lead regimen [news · 2026-05-06].
- Submitted a substantial modification to European regulators for Teverelix, supporting a planned Phase 2b study in high cardiovascular-risk prostate cancer patients, representing a ~$4 billion annual market opportunity [news · 2026-06-08].
- Submitted an IND application in the UAE for PRECISION-E2, a Phase 2a genomics-enabled trial of Teverelix in women with symptomatic endometriosis [news · 2026-06-11].
- Advanced SkinJect into registrational development for Gorlin Syndrome (a rare disease) with a Phase 2b protocol submission to the U.S. FDA [news · 2026-06-03].
What works
- SkinJect Phase 2 data showed an 80% overall response rate (ORR) and dose-response, with the 200µg cohort achieving 55% complete response, positioning it for registrational trials [news · 2026-03-26][news · 2026-05-06].
- Teverelix is being developed for multiple large-market indications (prostate cancer, endometriosis) with potential first-in-class long-acting injectable GnRH antagonist profile [news · 2026-06-08][news · 2026-06-11].
- Non-dilutive $22M financing provides capital to support clinical development and extends cash runway beyond two years, reducing near-term dilution risk [news · 2026-05-28].
What to weigh
- All programs are in Phase 2 or earlier; no product has received marketing approval, and there is no revenue from product sales [news · 2026-03-25].
- Clinical results are from relatively small datasets (e.g., 90-patient Phase 2 study for SkinJect); larger registrational trials carry execution and efficacy risks [news · 2025-12-15][news · 2026-05-06].
- The company operates in competitive therapeutic areas (non-melanoma skin cancer, GnRH antagonist market) with established and emerging therapies [news · 2026-01-05].
From the filings
Quoted directly from source documents.
SkinJect 200µg cohort achieved 55% complete response at Day 57.
“200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen”
News · May 6, 2026
$22M non-dilutive financing extends cash runway over two years.
“Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years”
News · May 28, 2026
Teverelix European submission supports Phase 2b in prostate cancer with $4B market.
“European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity”
News · June 8, 2026
SkinJect Phase 2b protocol submitted to FDA for Gorlin Syndrome.
“New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries”
News · June 3, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Phase 2 data are promising but larger registrational trials may not replicate results; high risk of failure in rare disease and oncology [news · 2026-05-06][news · 2026-06-03].
- Regulatory and approval uncertainty — SkinJect and Teverelix require FDA and EMA approvals; delays or rejections would impair pipeline value [news · 2026-06-08][news · 2026-06-03].
- Competitive market pressure — Both BCC and prostate cancer/endometriosis markets have established treatments; differentiation may be challenging [news · 2026-01-05].
- Reliance on non-dilutive financing — Although $22M extends runway, future capital needs may require additional financing, potentially dilutive [news · 2026-05-28].
What to watch
- Initiation of Teverelix Phase 2b study in high-risk prostate cancer following European regulatory submission [news · 2026-06-08].
- Progress of SkinJect Phase 2b registrational trial for Gorlin Syndrome and FDA feedback on the NDA-enabling protocol [news · 2026-06-03].
- Clinical data and regulatory updates from the Teverelix Phase 2a endometriosis trial (PRECISION-E2) in the UAE [news · 2026-06-11].
- Presentations at BIO 2026 (June 22) and other conferences to highlight pipeline data and potential partnership opportunities [news · 2026-06-22].
Sources: News · Generated July 14, 2026 · How we verify sources →
Unlock the full Medicus Pharma Ltd. dossier
Sign in free to see catalysts, full pipeline, financials, FDA decisions, news, and run live AI deep-dives.
Free account includes:
- Full pipeline, catalysts, financials & FDA decisions for Medicus Pharma Ltd.
- 200 free AI credits / month to run live Spotter deep-dives
- Watchlist, news alerts & the biotech event calendar
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.2 months
D/E 4.52 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Medicus Pharma Ltd.?
Medicus Pharma Ltd. (MDCX) is a biotech/life sciences company advancing two clinical-stage programs: SkinJect (non-invasive treatment for non-melanoma skin cancer) and Teverelix (a GnRH antagonist for oncology and women's health), with recent Phase 2 data and regulatory submissions supporting registrational development.
What is Medicus Pharma Ltd.'s lead drug candidate?
Medicus Pharma Ltd.'s most advanced tracked candidate is d-mna (Phase 2) for basal cell carcinoma (BCC) of the skin.
Who is the CEO of Medicus Pharma Ltd.?
Dr. Raza Bokhari M.B.A., M.D. is the chief executive officer of Medicus Pharma Ltd. (MDCX).
Where is Medicus Pharma Ltd. headquartered?
Medicus Pharma Ltd. (MDCX) is headquartered in West Conshohocken, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Medicus Pharma Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.